Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30494447 | 0.85 | MGAM (0.55) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL15144424 | 0.83 | MGAM (0.43) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL7270121 | 0.82 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL1131192 | 0.82 | THRB (0.53) | GAAMGAMSIMGAM2ALDH1A1 | |
| Ethyl Pyruvate SCHEMBL1331224 | 0.82 | — | — | |
| Ethyl Pyruvate SCHEMBL28156490 | 0.82 | GLO1 (0.61) | GAAMGAMSIMGAM2ALDH1A1 | |
| Ethyl Pyruvate SCHEMBL25538 | 0.82 | — | — | |
| SCHEMBL20100418 | 0.80 | THRB (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL1006090 | 0.80 | ALDH1A1 (0.65) | GAAMGAMSIMGAM2ALDH1A1 | |
| Ethyl Pyruvate SCHEMBL30913010 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815946-B2 | Inhibition of proliferation and fibrotic response of activated corneal stromal cells | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-08-26 | — | — | US | claimed |
| US-20090239947-A1 | Inhibition of proliferation and fibrotic response of activated corneal stromal cells | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2009-09-24 | — | — | US | claimed |
| EP-1233767-B1 | PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION | XANTHUS LIFE SCIENCES INC (CA) | 2006-04-12 | — | — | EP | claimed |
| US-20050059738-A1 | Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion | XANTHUS LIFE SCIENCES, INC. (CA) | 2005-03-17 | — | — | US | claimed |
| EP-1233767-A4 | PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION | XANTHUS LIFE SCIENCES INC (CA) | 2005-02-09 | — | — | EP | claimed |
| US-6846842-B2 | Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion | BETH ISRAEL DECONESS MEDICAL CENTER, INC. (US) | 2005-01-25 | — | — | US | claimed |
| US-20030073743-A1 | Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion | XANTHUS LIFE SCIENCES, INC. (CA) | 2003-04-17 | — | — | US | claimed |
| EP-1233767-A1 | PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION | Xanthus Life Sciences, Inc. (CA) | 2002-08-28 | — | — | EP | claimed |
| WO-2001024793-A1 | PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION | XANTHUS LIFE SCIENCES, INC. (CA) | 2001-04-12 | — | — | WO | claimed |
| US-20260076935-A1 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2026-03-19 | — | — | US | disclosed |
| EP-4683625-A2 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | The Trustees Of Columbia University In The City Of New York (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025058667-A2 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2024075474-A1 | PARTICULATE COMPOSITION, COATING MATERIAL, INK, AND ADHESIVE | 三菱ケミカル株式会社 | 2024-04-11 | — | — | WO | disclosed |
| EP-4329743-A1 | PYRUVATE ESTERS FOR THE TREATMENT OF VIRAL DISEASES | Birkenmeier, Gerd (DE) | 2024-03-06 | — | — | EP | disclosed |
| WO-2006108682-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006012373-A2 | COMBINATION THERAPIES OF HMGB AND COMPLEMENT INHIBITORS AGAINST INFLAMMATION | CRITICAL THERAPEUTICS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1494659-B1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1494659-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | Critical Therapeutics, Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20030232884-A1 | New pharmaceutical formulation | CRITICAL THERAPEUTICS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003088955-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMINE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076935-A1 | PREVENTION AND TREATMENT OF CONDITIONS USING ETHYL PYRUVATE | PC, PDK1, PDK4 | GAA 1176/4885MGAM 1754/4885SI 3225/4885 |
| US-20030232884-A1 | New pharmaceutical formulation | LIPA, CEL, LDHA | GAA 82/4885MGAM 347/4885SI 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.